Latest Commercial Sales News

Mesoblast Limited reported its first commercial sales of FDA-approved Ryoncil, generating $48.7 million in net product sales for the half-year ended December 31, 2025, while reducing its net loss by 16%. The company also secured a $125 million five-year credit facility, restructuring its debt to support ongoing commercialization and development.

Neuren Pharmaceuticals reports a 15% rise in 2025 royalties from its partner Acadia’s DAYBUE sales, with strong 2026 guidance signalling further growth. The launch of a new powder formulation and ongoing regulatory efforts in Europe and Japan add to the momentum.

XReality Group has reported its strongest half-year performance yet, driven by rapid growth in its Operator XR business focused on immersive training solutions for defence and law enforcement.

xReality Group Limited has reported a robust half-year performance with revenue climbing 41% to $10.4 million, driven by rapid expansion of its Operator XR platform. EBITDA surged 190%, underscoring the company’s successful pivot to software-led immersive training solutions.

Nickel Industries reported a reduced loss after tax of $41.2 million for 2025, underpinned by steady production and strategic progress on its ENC HPAL project and sustainability initiatives.

PolyNovo Limited reported a robust 25.2% increase in half-year revenue to A$75 million, driven by strong U.S. sales and product growth, despite a near break-even net profit impacted by a manufacturing slowdown and a fire at its R&D lab.

Li-S Energy narrows its loss to $1.21 million in H1 2026, propelled by a $7.8 million ARENA grant and key manufacturing milestones including Australia’s first lithium metal foil production line. Strategic defence and aerospace partnerships bolster its commercialisation drive.

The US Department of Commerce has finalized hefty antidumping and countervailing duties on Chinese graphite active anode materials, a move expected to strengthen Syrah Resources’ competitive edge in North America and accelerate its US operations.

Memphasys Limited has secured Therapeutic Goods Administration approval for its Felix™ System two months ahead of schedule, enabling immediate commercial sales and clinical use in Australia.

Memphasys has lodged regulatory submissions for its Felix™ System in Australia and India, following CE Mark approval, while progressing UK market entry under the CE Mark transition framework.

Wide Open Agriculture has made significant strides in expanding its intellectual property and commercial footprint, including a new patent for lupin protein milk and first sales of lupin oil, while progressing plans for a large-scale manufacturing facility in Western Australia.

Sparc Technologies has marked a significant milestone with sustained hydrogen production at its pioneering pilot plant and secured key patents, while also achieving its first commercial sale of graphene additives.